Health Care & Life Sciences » Pharmaceuticals | Intra-Cellular Therapies Inc.

Intra-Cellular Therapies Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
2,737.00
577.30
91.40
330.70
245.80
368.70
SG&A Expense
28,980.60
31,538.50
105,765.70
118,392.70
102,872.10
161,898.10
EBIT
26,266.90
30,986.70
105,814.00
118,258.90
102,840.10
162,266.80
Non Operating Income/Expense
-
7.10
-
-
-
-
Interest Expense
613.00
-
-
36.80
-
-
Pretax Income
26,850.20
30,689.90
104,791.50
115,360.60
98,834.30
155,125.80
Income Tax
18.00
1.60
1.60
1,065.70
1,060.90
1.60
Consolidated Net Income
26,868.20
30,691.50
104,793.10
116,426.30
97,773.40
155,127.40
Net Income
26,868.20
30,691.50
104,793.10
116,426.30
97,773.40
155,127.40
Net Income After Extraordinaries
26,868.20
30,691.50
104,793.10
116,426.30
97,773.40
155,127.40
Net Income Available to Common
26,868.20
30,691.50
104,793.10
116,426.30
97,773.40
155,127.40
EPS (Basic)
1.56
1.07
2.91
2.69
2.12
2.84
Basic Shares Outstanding
17,260.80
28,650.10
36,069.20
43,240.20
46,181.90
54,707.90
EPS (Diluted)
1.56
1.07
2.91
2.69
2.12
2.84
Diluted Shares Outstanding
17,260.80
28,650.10
36,069.20
43,240.20
46,181.90
54,707.90
EBITDA
26,243.60
30,961.20
105,674.40
118,062.00
102,626.30
161,898.10
Non-Operating Interest Income
29.60
303.90
1,022.50
2,935.10
4,005.90
7,141

About Intra-Cellular Therapies

View Profile
Address
430 East 29th Street
New York New York 10016
United States
Employees -
Website http://www.intracellulartherapies.com
Updated 07/08/2019
Intra-Cellular Therapies, Inc. is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Its lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. The company also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease, and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.